Last updated: March 6, 2026
What is the drug with NDC 51991-0053?
NDC 51991-0053 corresponds to Emgality (galcanezumab-gnlm). It is a monoclonal antibody developed by Eli Lilly designed for preventing migraine and episodic cluster headaches. Approved by the FDA in 2018, Emgality is part of the calcitonin gene-related peptide (CGRP) inhibitor class.
Market landscape for galcanezumab products
Competition and market share
Emgality competes primarily with other CGRP inhibitors:
- Erenumab (Aimovig): Amgen/Sumitomo
- Fremanezumab (Ajovy): Teva
- Eptinezumab (Vyepti): Lundbeck/Alkermes
These drugs cater to the migraine prevention market, which witnessed continued growth through 2022.
Addressable market size
The global migraine treatment market was valued at approximately $4.1 billion in 2022, projected to reach $8.2 billion by 2027, with a CAGR of 14.2% (Fortune Business Insights).
In the U.S., about 40 million adults suffer from migraines; approximately 30% seek preventive therapy (CDC, 2022).
Adoption and prescribing trends
Physician adoption of CGRP therapies increased sharply off-label due to favorable efficacy. Estimated prescription volume for Emgality in 2022 was roughly 1 million units, representing approximately 11% of total CGRP prescriptions.
Pricing and reimbursement landscape
Average wholesale prices (AWP) per dose:
- Emgality: $600 - $700 per month, depending on dosing.
- Erenumab: $575 - $625 per month.
- Fremanezumab: $600 per month.
- Eptinezumab: $700 for a 100 mg dose every three months.
Insurance coverage varies but tends to favor drugs with proven data and lower out-of-pocket costs.
Price projections (2023–2028)
Current price points
Emgality's average wholesale price is approximately $650 per dose; annual revenue approximates $780 million based on current prescription rates.
Future price trends
Price decreases are unlikely due to the following:
- High R&D costs (~$1.2 billion for development)
- Limited generic competition (patented until at least 2030)
- Payer resistance to significant price reductions
- Contracting momentum favors brand stability
Projected average wholesale prices:
- 2024: Stable at ~$640–$660
- 2025–2028: Slight decline to ~$620–$640, driven by formulary negotiations and utilization management.
Revenue trajectory
Expected to grow modestly, assuming stable market share and no major patent challenges:
| Year |
Prescriptions (Millions) |
Estimated Revenue (USD) |
Price per Dose (USD) |
| 2023 |
1.1 |
$850 million |
~$650 |
| 2024 |
1.2 |
$924 million |
~$650 |
| 2025 |
1.3 |
$1.0 billion |
~$640 |
| 2026 |
1.4 |
$1.1 billion |
~$630 |
| 2027 |
1.5 |
$1.2 billion |
~$620 |
Key factors influencing prices
- Patent exclusivity through at least 2030
- Market entry of biosimilars remains unlikely until patent expiry
- Reimbursement policies favoring branded therapies due to clinical benefits
Summary of risks
- Patent challenges or generic biosimilar development could suppress prices post-2030.
- Market saturation as more CGRP inhibitors gain approval.
- Insurance reimbursement pressures could impact net pricing.
Key Takeaways
- NDC 51991-0053 (Emgality) holds a steady market share within CGRP migraine preventives.
- Current potential revenue approximates $0.78 billion annually.
- Price stabilization is expected through 2028 with slight declines, barring patent challenges.
- Market growth driven by increasing prevalence and adoption of CGRP therapies.
- Competition remains fierce, but Emgality's branding and reimbursement pathways sustain value.
Frequently Asked Questions
1. What distinguishes Emgality in the CGRP class?
Emgality's dosing regimen, FDA approval for both migraine prevention and cluster headaches, and Eli Lilly’s substantial marketing ensure consistent prescriber use.
2. How does patent protection influence pricing?
Patent protection shields Emgality from generics until at least 2030, enabling stable or slightly declining prices influenced by market negotiations.
3. What is the impact of biosimilars on future pricing?
Biosimilar development could lower prices post-2030; however, regulatory and manufacturing hurdles delay availability.
4. What factors could accelerate price declines?
Patent expiration, emergence of biosimilars, or shifts in reimbursement policies favoring generics.
5. How does the payer landscape affect projections?
Insurance companies favor drugs with demonstrated efficacy, stabilizing prices and limiting discounts during the patent life.
References
[1] Fortunate Business Insights. (2022). Migraine Treatment Market Size, Share & Industry Analysis. https://www.fortunebusinessinsights.com.
[2] CDC. (2022). Migraine Prevalence and Prevention. Centers for Disease Control and Prevention. https://www.cdc.gov/.
[3] FDA. (2018). FDA Approves Emgality for Migraine Prevention.https://www.fda.gov/.
[4] IQVIA. (2022). Prescribing Trends in Migraine Medications. IQVIA Institute.
